NCT04829656Befejeződött
The PACE-DLB Study
Identifying Factors Predicting ACcurately End-of-Life in Dementia With Lewy Bodies and Promoting Quality End-of-Life Experiences: the PACE-DLB Study
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jan. 13.
Rövid összefoglaló (regiszter, angolul)
The PACE-DLB Study is for people with at least moderate dementia with Lewy bodies (DLB) and their primary caregiver. The study's goals are to learn more about the experiences of people with DLB and their caregivers as DLB progresses, and what happens as the end of life of the person with DLB approaches. Participants are enrolled through one of five Lewy Body Dementia Association (LBDA) Research Center of Excellence clinics, or directly via the LBDA. People with DLB will enroll into the study along with their primary informal caregiver, such as the family member or friend who is involved in most of their care and attends the majority of their medical appointments. A legally authorized representative (LAR) for the person with DLB will consent to participate in the study on the person's behalf. If the person with DLB resists taking part in the study, the pair will not be enrolled. The study consists of questionnaires about the progression of the person's dementia and the experiences of the caregiver. The person with DLB will complete one questionnaire themselves if they are able to. If the pair is enrolled at a LBDA Research Center of Excellence clinical site, and completes study visits in-person, a brief physical exam of the person with DLB will be completed by a clinician. Study participation will last for three years, or until the person with DLB dies. Study visits take place every six months, either virtually or in person at a clinical study site. If the person with DLB dies during the study, the caregiver will complete one final virtual study visit three months afterward. Specific Aims of the PACE-DLB Study: 1. To determine predictors of the end of life (death within 6 months) in the DLB population. Hypotheses: Predictors of death within 6 months for individuals with DLB will include symptoms (e.g. worsening hallucinations, fluctuations) not captured in existing dementia end-of-life prediction tools. 2. To identify whether change in caregiver measures can predict the end of life in the DLB. Hypotheses: The investigators hypothesize that there will be worsening caregiver burden, depression, grief, and quality of life preceding the last 6 months of life, controlling for variables such as resilience, support, and living situation. 3. To identify the impact of demographics, health care factors, and specific DLB symptoms on patient quality of life and caregiver experiences at the end of life of the person living with DLB. Hypotheses: Location (rural, urban, suburban), provider experience (e.g. specialist vs not), patient residence (e.g. home, skilled nursing), degree of behavioral symptoms, caregiver type (spouse vs child vs other), and caregiver characteristics (self-efficacy, perceived social support, resilience, and coping) will affect patient and informal caregiver experiences at the patient's end of life, including patient and caregiver quality of life and caregiver well-being, depression, burden, grief, and satisfaction with end-of-life care.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 378 (tényleges)
- Első benyújtás
- 2021. márc. 22.
- Kezdés
- 2021. febr. 25.
- Elsődleges befejezés
- 2025. dec. 31.
- Fő szponzor
- University of Florida
- Betegségek
- Lewy-testes demencia
- NCT-szám
- NCT04829656
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Bevont résztvevők: 378
- 2021. febr. 25. és az elsődleges befejezés (2025. dec. 31.) között
- 5 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Patient participant diagnosed with dementia of less than moderate severity
- Patient with dementia resists participation
- Patient participant with dementia not expected to live at least 6 months
Egyéb
- Non-U.S. residents
- Virtual cohort ONLY: Patient participant receives medical care from a LBDA Research Centers of Excellence clinic
Kiket keres a vizsgálat
- Patient and caregiver willing to participate as a dyad (patients will need a legally authorized representative to consent on their behalf given the requirement for at least moderate dementia, but patients who resists participating in the study will not be enrolled)
- U.S. residents (i.e., individuals accessing the LBDA from outside the U.S. will be excluded)
- Patient with a clinical diagnosis of DLB
- Patient with moderate severity dementia as assessed by the Quick Dementia Rating System (QDRS, with a score of >12 OR ≥2 in at least 3 domains suggestive of moderate dementia)
- Caregiver telephone interview for cognitive status (TICS) score of >31 to ensure that the caregiver is able to reliably complete study visits
- Patient participant expected to live at least 6 months (so that at least a baseline visit and 1 follow up visits is expected to be completed)
Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (5)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| University of Michigan | Ann Arbor | Egyesült Államok | Ismeretlen állapot |
| University of Virginia | Charlottesville | Egyesült Államok | Ismeretlen állapot |
| University of Florida | Gainesville | Egyesült Államok | Ismeretlen állapot |
| University of Miami | Miami | Egyesült Államok | Ismeretlen állapot |
| Mayo Clinic | Rochester | Egyesült Államok | Ismeretlen állapot |
Kapcsolódó publikációk
- Fluctuations correlates in advanced dementia with Lewy bodies: A longitudinal study.Alzheimers Dement (Amst) · 2026 · PMID 42953268
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.